Zevra CHMP Negative Opinion on Arimoclomol
Analysis based on 30 articles · First reported Jul 24, 2026 · Last updated Aug 11, 2026
The negative CHMP opinion triggered a sharp decline in Zevra Therapeutics' stock price, eroding shareholder value and raising concerns about the company's lead product's commercial prospects in Europe. The subsequent securities investigation adds legal and reputational risk, potentially affecting investor confidence and the company's ability to secure regulatory approval or partnerships.
On July 24, 2026, the European Union — European Medicines Agency's European Union — Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa, for the treatment of Niemann-Pick disease type C (NPC). Zevra Therapeutics, the developer of arimoclomol, saw its shares fall approximately 24% in pre-market trading, marking the stock's worst single-day percentage loss in more than five years. Zevra announced its intention to request a re-examination of the CHMP opinion and to continue providing arimoclomol to eligible patients through its global Expanded Access Program. Following the regulatory setback, Levi & Korsinsky, a securities litigation firm, commenced an investigation into potential violations of federal securities laws by Zevra, focusing on public statements about arimoclomol's regulatory prospects, including a May 8, 2024 earnings call statement by CEO Neil F. McFarlane that arimoclomol would 'most likely be the only approved foundational therapy for patients with NPC.' The investigation seeks to determine whether Zevra made materially false or misleading statements regarding arimoclomol's regulatory status.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard